Brian Murphy, PhD

Brian Murphy, PhD

Brian Murphy, PhD, is a medical/science writer and educator who has written over 300 resource articles about rare diseases. He holds a BS from Georgia Institute of Technology and a PhD from Case Western Reserve University, both in Biomedical Engineering. After graduation, Brian worked as a clinical neural engineer to help restore movement in spinal cord injured patients by reconnecting their brain to their paralyzed muscles using experimental medical devices. In addition to resource pages, Brian has also authored/co-authored several research articles in journals including The Lancet, Journal of Neural Engineering, and PLOS ONE.

All articles by Brian Murphy, PhD

Numeric Rating Scale Could Assess NMOSD Spasticity

Self-reported scores on the Numeric Rating Scale (NRS) from patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) were correlated with physicians’ scores on the Modified Ashworth Scale (MAS) (r =.934; P <.001), as published in Multiple Sclerosis and Related Disorders. “Patients’ self-reported NRS score had a good correlation with clinician-evaluated MAS score…

Anti-SSA/Ro Antibody Might Predict NMOSD Severity

The presence of anti-Sjögren’s syndrome A/Ro (anti-SSA/Ro) antibodies may be associated with disease activity and more severe disability in patients with neuromyelitis optica spectrum disorder (NMOSD), according to results of a study published in Multiple Sclerosis and Related Disorders. The researchers showed that patients with anti-SSA/Ro antibodies were more likely to be positive (89.2% vs…

Researchers Emphasize Clinical and Immunohematology Testing for CAD

A patient was diagnosed with cold agglutinin syndrome (CAS) after the discovery of cold-antibody autoimmune hemolytic anemia (cAIHA) and splenic marginal zone lymphoma (MZL), as published in Hematology, Transfusion and Cell Therapy. CAS was recently described as a separate but similar entity to cold agglutinin disease (CAD). “In [CAD], patients may have a B-cell clonal…

Switching to BAY 81-8973 Could Help Optimize Hemophilia Treatment

Patients with hemophilia A who switched to BAY 81-8973 (octocog alfa; Kovaltry®) from other standard half-life (SHL) factor VIII (FVIII) products maintained already favorable outcome rates with a possible improvement in half-life, as published in Haemophilia. The patients enrolled in the study had a median annualized bleeding rate (ABR) and annualized joint bleeding rate (AJBR)…

Corticosteroids Associated With Delayed Complications in Nonambulatory DMD

The use of corticosteroids in patients with Duchenne muscular dystrophy (DMD) after their loss of ambulation (LOA) may delay the onset of abnormal percent predicted forced vital capacity (ppFVC), according to an article published in Muscle & Nerve. Boys with DMD who continued corticosteroid use for at least 1 year after LOA had a statistically…

Inhibition of TRCP6 Shows Therapeutic Potential in PAH

Inhibition of transient receptor potential channel 6 (TRPC6) may be a novel therapeutic approach for treating pulmonary arterial hypertension (PAH), according to a new study published in the American Journal of Physiology – Lung Cellular and Molecular Physiology. The results showed that the administration of BI-749327, a selective blocker of TRCP6, resulted in roughly 50%…

COVID-19 May Be Benign in Patients With Late-Onset Pompe Disease

COVID-19 disease course may be benign in some patients with late-onset Pompe disease (LOPD), according to a new case series published in Muscle & Nerve. The results showed that 4 patients with LOPD who had pre-existing pulmonary involvement had mild to moderate illnesses from COVID-19 did not require hospitalization. Respiratory Pompe symptoms remained stable in…

Next post in Pompe News Briefs